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Aims: The aim of this study was to evaluate the population pharmacokinetics (PopPK)
of olanzapine in children and devise a model-informed paediatric dosing scheme.
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Methods: The PopPK of olanzapine was characterized using opportunistically col-
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lected plasma samples from children receiving olanzapine per standard of care for
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any indication. A nonlinear mixed effect modelling approach was employed for model
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development using the software NONMEM (v7.4). Simulations from the developed
PopPK model were used to devise a paediatric dosing scheme that targeted compara-
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ble plasma exposures to adolescents and adults.
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Results: Forty-five participants contributed 83 plasma samples towards the analysis.
The median (range) postnatal age and body weight of participants were 3.8 years
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(0.2–19.2) and 14.1 kg (4.2–111.7), respectively. The analysis was restricted to pharmacokinetic (PK) samples collected following enteral administration (oral and feeding
tube). A one-compartment model with linear elimination provided an appropriate fit
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to the data. The final model included the covariates body weight and postmenstrual

9

The Emmes Company, LLC, Rockville, MD,
USA

age (PMA) on apparent olanzapine clearance (CL/F). Typical CL/F and apparent volume of distribution (scaled to 70 kg) were 16.8 L/h (21% RSE) and 663 L (13% RSE),
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respectively. Developed dosing schemes used weight-normalized doses for children
≤6 months postnatal age or <15 kg and fixed doses for children ≥15 kg.
Conclusion: We developed a paediatric PopPK model for enterally-administered
olanzapine. To our knowledge, this analysis is the first study to characterize the PK of
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olanzapine in participants ranging from infants to adolescents. Body weight and PMA
were identified as influential covariates for characterizing developmental changes in
olanzapine apparent clearance.
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I N T RO DU CT I O N

use of atypical (second generation) antipsychotics, which represent the
most common subtype prescribed to children.4 Despite recent paediat-

Use of antipsychotic medications among children has increased dramatically over the last two decades.

1–3

This trend is largely driven by

ric regulatory approvals in this drug class, approximately two-thirds of
atypical antipsychotics prescribed to children are for non-approved

PI Statement: The authors confirm that the Principal Investigator for this paper is Christoph P. Hornik and that he had direct clinical responsibility for patients.
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indications (i.e., off-label).5 This high prevalence of off-label medication
use in children reflects the lack of appropriate safety, efficacy and phar-

What is already known about this subject

macokinetic (PK) studies in this population and places children at higher
risk of experiencing adverse drug events.6–8 Of additional concern is

• Olanzapine is a multi-acting receptor-targeted (atypical)

that even when prescribed for labelled indications, children experience

antipsychotic administered to children for a variety of

some antipsychotic-associated adverse drug events (e.g., sedation and

labelled and off-label indications.

weight gain) more often than adults.9 Consequently, to promote the

• The pharmacokinetics (PK) of olanzapine have been pre-

safe and effective use of antipsychotic medications in children,

viously characterized in adults and adolescents; however,

paediatric-focused safety, efficacy and PK investigations are needed.

the effects of growth and development on olanzapine

Olanzapine is a multi-acting receptor-targeted (atypical) antipsychotic

that

exhibits

potent

antagonism

towards

PK, especially in children <10 years, remains unknown.

serotonin

(5-HT2A/2B/2C), dopamine (D2), histamine (H1) and adrenergic recep-

What this study adds

tors (α1).10,11 Based on current US Food and Drug Administration
(FDA) approved labelling, olanzapine is indicated for the treatment of

• This study characterizes developmental changes in

schizophrenia and bipolar I disorder (manic or mixed episodes) as a

olanzapine PK in a cohort of 45 subjects ranging in post-

single agent in children ≥13 years; and depressive episodes associated

natal age from 2 months to 19 years.

with bipolar I disorder in combination with fluoxetine for children

• Body weight and postmenstrual age are influential

≥10 years.12 In addition, olanzapine is administered off-label to chil-

covariates for characterizing developmental changes in

dren for a myriad of indications including eating, tic, attention-defi-

olanzapine apparent clearance.

cit/hyperactivity, autism spectrum and pervasive developmental

• We developed a paediatric dosing scheme that provided

disorders and delirium.13–18 Despite olanzapine's diverse usage, the

comparable plasma exposures to adults and adolescents.

relationship between specific PK thresholds (e.g., pre-dose plasma

The proposed dosing scheme can be used to guide the

concentrations) and therapeutic efficacy remains ill-defined.19–23 Fur-

development of prospective safety and efficacy studies

thermore, few studies exist characterizing the PK of olanzapine in

for olanzapine in children.

children, especially those <10 years.24,25
In adults, the oral bioavailability of olanzapine is reported to be
≥65%.26 On average, plasma protein binding is 93% and attributed to
both albumin and α-1-acid glycoprotein.12,26 Olanzapine is primarily
cleared by hepatic metabolism via several enzymes (CYP1A2, CYP2D6,
CYP2C8, UGT1A4, and flavin-containing monooxygenase-3), while
7% of the orally administered dose is excreted unchanged in
urine.26–28 Previous adult PK investigations indicate that smoking sta-

standard of care as administered by their treating caregiver were eligi-

tus, sex and race (African American) are significant covariates towards

ble for enrolment. Exclusion criteria for the POPs trial included failure

olanzapine apparent oral clearance (CL/F).29,30 In adolescents, body

to obtain consent/assent or known pregnancy as determined by inter-

25

In this

view or testing. Additional exclusion criteria instituted for the current

study, we sought to evaluate the population pharmacokinetics (PopPK)

PK analysis included participants receiving dialysis (intermittent or

of olanzapine in children (infants to adolescents) and characterize

continuous) or extracorporeal membrane oxygenation. The study pro-

covariates that contribute towards its PK variability. In addition, using

tocol was reviewed and approved by each participating institution's

the developed PopPK model, we aimed to devise a model-informed

review board.

weight and sex have been identified as influential covariates.

paediatric dosing strategy.

2.2
2

|

Drug dosing and sample collection

METHODS

|

Dosing information was collected for up to eight doses prior to the

2.1

|

Patient population

sampling dose (last dose prior to sample collection). Since the POPs
trial employs an opportunistic study design, the timing of plasma sam-

PK samples used to develop the PopPK model were collected as part

ple collections was dependent on standard of care laboratory assess-

of the Pharmacokinetics of Understudied Drugs Administered to Chil-

ments. However, parents/guardians were also given the option to

dren per Standard of Care (POPs) trial, a prospective, multi-centre, PK

allow sample collections at different times than standard of care labo-

study in children less than 21 years of age (NICHD-POP01–2011;

ratory tests. Results from standard of care laboratory tests (e.g., basic

ClinicalTrials.gov #NCT01431326) conducted by the Eunice Kennedy

metabolic panel) were recorded if collected within 72 hours of the

Shriver National Institute of Child Health and Human Development

sampling dose. The PK analysis dataset was generated by The Emmes

Pediatric Trials Network (PTN). Children who received olanzapine per

Company, LLC.
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2.3

Analytical methods

|

Equations used to estimate FFM and LBM are described in the supplementary

materials.39,40

Fixed

allometric

relationships

Olanzapine concentrations in plasma were quantified using a validated

(i.e., exponent = 0.75) were employed to describe the relationship

liquid chromatography–tandem mass spectrometry (LC/MS–MS)

between clearance (CL) and inter-compartmental clearance (Q) with

assay (Frontage Laboratories, Exton, PA, USA). A Shimadzu series

body size. For volume of distribution (V), a linear relationship was

high-performance liquid chromatography system (Pump LC-20 AD;

assumed (i.e., exponent = 1). Typical PK parameter values were

Autosampler SIL-20 AC HT) and a Sciex API 5000 system (mass spec-

centred towards a WT of 70 kg, LBM of 54 kg, or FFM of 56 kg.

trometer) were used for sample analysis. The separation was achieved
using a Phenomenex Synergi MAX-RP 80 Å column (4 μm, 2 ×
50 mm) at room temperature by gradient elution with 2mM ammo-

2.4.2

|

Covariate testing

nium acetate in water (mobile phase A) and acetonitrile:water:ammonium hydroxide (95:5:0.05; mobile phase B). Intra- and inter-run

Forward selection and backward elimination were used to evaluate the

accuracy and precision assessed at four concentration levels (0.05,

influence of continuous and categorical covariates on olanzapine

0.15, 6 and 37.5 ng/mL) were within the FDA bioanalytical assay vali-

PK. The following continuous covariates were assessed: postnatal age

31

dation criteria (e.g., ±15–20%).

The lower limit of quantification for

(PNA; years), postmenstrual age (PMA; weeks), albumin (ALB; g/dL)
and serum creatinine (SCR; mg/dL). In addition, the following categori-

olanzapine was 0.05 ng/mL.

cal variable were assessed: sex (SEX); African American (RACE); obesity, defined as a body mass index ≥95th percentile for age and sex

2.4

Population pharmacokinetic analysis

|

based on Centers for Disease Control and Prevention (CDC) growth
charts41 (OBESE); absence of food intake 2 hours prior to

Olanzapine plasma concentration–time data were analysed using

dose administration (FAST); formulation, tablet/capsule vs. crushed

nonlinear mixed effects modelling using the software NONMEM (ver-

tablet/suspension/solution (FORM); and dose administration via tube

sion 7.4, Icon Solutions, Ellicott City, MD, USA). The first-order condi-

(TUBE). Covariates were directly tested on all model parameters with

tional estimation method with interaction was used for all model runs.

added IIV terms. Statistical significance during covariate testing was

Run management was performed using Pirana (version 2.9.7).32 Non-

asserted by comparing changes in objective function values (OFV) to

parametric bootstraps were performed with Perl-speaks-NONMEM

critical values corresponding to chi-squared distributions with degrees

33

Data manipulation and visualizations were per-

of freedom equal to the difference in estimated parameters between

formed in R (version 3.4.3, R Foundation for Statistical Computing,

nested models and P-values of .05 (forward selection) and .01 (back-

Vienna, Austria) and RStudio (version 1.1.383, RStudio, Boston, MA,

ward elimination). Several imputation strategies were employed to

USA) with the packages lattice, xpose4, cowplot, and ggplot2.34–37

account for missing covariates during the covariate testing process.

(version 3.6.2).

For PMA, which represents the sum of PNA and gestational age (GA),
a GA of 40 weeks was assumed, if missing. GA age was reported for all

2.4.1

|

children <120 days PNA. For children ≥120 days PNA, GA was

Base model development

reported, if available. An age-segmented approach was used to impute
One- and two-compartment structural models were explored. Inter-

missing ALB and SCR values. Missing entries were imputed using the

individual variability (IIV) on PK model parameters was described using

median value of covariate entries from participants within different
age groups (PNA < 2 years, ≥2 and <6 years, ≥6 and <12 years and

an exponential relationship (Equation 1):
 
Pij = θPop,j  exp ηij

≥12 years) for whom the covariate of interest was reported. Particið1Þ

pants were assumed to be non-black/non-African American if the race
was missing. Participants for whom obesity status was undefined

where Pij denotes the estimate of parameter j in the ith individual;

(i.e., PNA < 2 years or missing body mass index) were assumed to be

θPop,j is the typical population value for parameter j; and ηij denotes

non-obese. Food intake prior to dose administration was only recorded

the deviation from the typical population value for parameter j in the

for sampling doses. For non-sampling doses, fed-state conditions were

ith individual. The random variable η is assumed to be normally distrib-

assumed. All other covariates were non-missing within the dataset.

uted with a mean zero and variance ω2. Estimation of diagonal and
block matrices were explored to describe covariance between IIV
terms. Proportional, additive and combined (proportional plus addi-

2.4.3

|

Model evaluation

tive) residual error models were evaluated.
Based on standard practices, body size was empirically assumed

Model development was guided by diagnostic plots, successful mini-

to be an influential covariate for describing olanzapine PK.38 Corre-

mization and plausibility, as well as precision of parameter estimates,

spondingly, competing body size measures, including body weight

OFV and shrinkage values. Precision of parameter estimates from the

(WT), fat-free mass (FFM) and lean body mass (LBM), were assessed

final PopPK model were evaluated using non-parametric boo-

for model inclusion prior to evaluation of other covariates.

tstrapping (1000 replicates) to generate 95% confidence intervals.
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2.4.4

|

Statistical analysis

exposures to adults and adolescents. Average adult reference exposures were defined based on PK studies examining single-dose plasma

Individual PK parameter estimates (e.g., Bayesian post-hoc) from the

exposure following oral administration of olanzapine in healthy non-

final PopPK model were computed and summarized for participants

smoking adult volunteers. Reported AUC (from 0 to infinity) values

with PNA < 2 years, 2 to <6 years, 6 to <12 years, and ≥12 years. The

were averaged between publications, assuming linear PK between 2.5

Kruskal-Wallis test was performed to compare post-hoc clearance

and 10 mg doses, to provide reference exposures of 136.6 and

values (scaled to 70 kg) between age groups. A P-value of <.05 was

273.2 ng*h/mL for doses of 2.5 and 5 mg, respectively.46–48 To be

used to assert statistical significance.

defined as equivalent, median paediatric exposures derived by the
proposed dosing scheme were required to fall within 80–125% of the
adult reference value—a threshold that is widely used to assert bio-

2.5

| Pharmacokinetically-guided dose optimizations

equivalence (e.g., 80–125%).49 Instead of published studies directly
reporting olanzapine exposures in adolescents, reference adolescent

Optimal paediatric dosages were derived using a simulation-based

olanzapine exposures were estimated based on a previously published

methodology.

plasma

PopPK model by Lobo et al.,25 who evaluated olanzapine PK in ado-

concentration–time curve; AUC) were computed for a virtual paediat-

lescents with schizophrenia or bipolar I patients. Briefly, CL/F values

ric population of 4000 subjects (1000 subjects per PNA group:

were simulated for a virtual population of 1000 adolescent subjects

<2 years, 2–<6 years, 6–<12 years and ≥12 years). Virtual subjects

by incorporating both fixed and random-effect components. The pop-

were created using the PK-Sim® (v 7.2; https://github.com/Open-

ulation was generated using a similar demography as described above,

Systems-Pharmacology) population module. Subjects were created

except that the postnatal age and body weight ranges were con-

Paediatric

exposures

(area

under

the

based on a White-American population with a male-to-female ratio of

strained towards study participants included in Lobo et al.’s analysis

50:50. The span of postnatal ages and body weights for virtual sub-

(13–≤17 years and 41.1–148 kg, respectively). Adolescent exposures

jects were restricted to that of study participants who contributed

were estimated for fixed doses of 2.5 and 5 mg (Equation 2). Com-

data towards the PK analysis. All virtual subjects were considered full-

puted reference adolescent exposures were compared to adult refer-

term (GA = 40 weeks). This parameterization was based on a prelimi-

ence exposures, as well as paediatric exposures estimated based on

nary assessment of the PK dataset where only two of the seven sub-

the proposed dosing scheme.

jects with GA reported were considered premature (e.g., <37 weeks

Lastly, a comparative dosing simulation was conducted to evalu-

gestational age). For each virtual subject, an individualized CL/F value

ate olanzapine exposures (i.e., AUC) achieved using standard of care

was computed based on the final PopPK model, incorporating both

dosing (based on the current study cohort) vs. the proposed paediatric

fixed and random (e.g., IIV) effects. Assuming linear pharmacokinetics,

dosing scheme. Dosing simulations were conducted for virtual sub-

subject-specific plasma drug exposures (AUC) were derived using

jects ≤6 years PNA using the developed PopPK model.

Equation 2.

AUCi =

Dosei
CL=F i

ð2Þ

2.6

|

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to
where AUCi is the area under the plasma concentration–time curve

corresponding entries in http://www.guidetopharmacology.org, the

for a participant (exposure; mg*h/L), Dosei is the dose administered to

common portal for data from the IUPHAR/BPS Guide to PHARMA-

the participant (mg), and CL/Fi is the participant-specific apparent

COLOGY, and are permanently archived in the Concise Guide to

clearance value (L/h). The computed AUC represents both single-dose

PHARMACOLOGY 2017/18.

exposure, from time 0 to infinity (AUC0-inf), and steady-state exposure, from 0 to the end of the dosing interval (AUC0-tau).
In the absence of a well-defined exposure–response relationship

3

RE SU LT S

|

for olanzapine, a paediatric dosing scheme was derived to target comparable exposures to those achieved by adolescents and adults receiv-

3.1

|

Subject demographics

ing oral doses of 2.5 and 5 mg. These doses reflect initial dose
recommendations in adolescents for FDA labelled indications.12 In

Eighty-eight plasma samples from 47 participants were included in the

adults, 5 mg is the recommended initial dose of olanzapine when used

initial dataset. Five samples from two participants were excluded: one

in combination with fluoxetine for treating depressive episodes asso-

participant was receiving extracorporeal membrane oxygenation (one

ciated with bipolar I disorder and the lower limit of the recommended

sample) and the other was the sole participant for whom PK samples

initial dosage for treatment of schizophrenia (i.e., 5–10 mg).12 Further-

were collected following intravenous dose administration (four sam-

more, dosages between 2.5 and 5 mg represent initial/target doses

ples). This participant was excluded owing to the paucity of data to

used in adults for several non-labelled indications.42–45 Different pae-

characterize the intravenous disposition of olanzapine within the cur-

diatric dosing schemes were explored to achieve comparable drug

rent analysis. The PK analysis dataset consisted of 83 plasma samples
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from 45 participants. All plasma samples were above the analytical

3.2

|

Pharmacokinetic analysis

lower limit of quantification. Demographic characteristics of participants included in the PK analysis are shown in Table 1. Eleven (24.4%)

A one-compartment model with first-order absorption, linear elimina-

participants were obese. The median (range) number of doses

tion and combined residual error provided an appropriate fit to the

recorded per participant was 8 (1–23). The median (range) average

data. Empiric inclusion of alternative body size measures (FFM and

dose (per participant) was 0.1 (0.03–0.27) mg/kg. A median (range) of

LBM) as covariates on PK model parameters did not result in

2 (1–5) plasma samples were collected per participant. PK samples

improved model fits compared to actual body weight (WT); all models

were

conditions

had similar OFV and goodness-of-fit plots (Supplementary Table S1

(i.e., formulations, routes and feeding states), as specified in Table 2.

and Figure S1). Correspondingly, WT was selected as the preferred

Indications for olanzapine use were categorically recorded as schizo-

size scaler for development of the base model. Estimation of the first-

collected

under

varying

administration

phrenia, anxiety and ‘other’ for 1, 10 and 34 of the assessed partici-

order absorption rate constant (Ka) was associated with a high degree

pants, respectively. The dataset did not include information on

of imprecision and was subsequently fixed to 0.758 h−1, a value previ-

concomitantly administrated drugs that could alter olanzapine

ously defined for an adult PopPK model submitted to the FDA.50 The

disposition.

base model included IIV on CL/F solely. IIV terms on apparent volume

TABLE 1

Clinical and demographic data (at time of first PK sample), summarized by age group
Median (range) or n (%)

Variable

PNA < 2 years

n

17

Postnatal age (years)
Gestational age (weeks)a
Postmenstrual age (weeks)b
Body weight (kg)
Body mass index (kg/m2)c
Albumin (g/dL)

PNA 2–< 6 years

d

10

0.5 (0.2–1.7)
38 (33–39.6)
67.6 (46.7–126.4)
7.2 (4.2–11.5)
16.6 (12.8–19.6)

PNA 6–< 12 years

PNA ≥ 12 years

11

3.4 (2.2–5.2)

7

9.2 (6.2–11.3)

16.6 (12.7–19.2)

All
45
3.8 (0.2–19.2)

-

-

-

216.3 (156–312.6)

522.9 (365.3–632)

904.7 (702.1–1043.9)

38 (33–39.6)

14.1 (10.9–23)

29.1 (15.8–74.8)

80.2 (61–111.7)

14.1 (4.2–111.7)

16.9 (12.9–21.9)

17.2 (14.8–31.9)

32.1 (23.2–40.1)

18 (12.8–40.1)

239.7 (46.7–1043.9)

2.9 (2.4–3.3)

2.6 (2–3.3)

3.2 (2.1–4.3)

2.9 (1.5–3.9)

2.9 (1.5–4.3)

Serum creatinine (mg/dL)e

0.4 (0.1–0.5)

0.2 (0.1–0.4)

0.3 (0.2–0.6)

0.7 (0.5–1)

0.4 (0.1–1)

Female

11 (64.7)

5 (45.5)

4 (57.1)

24 (53.3)

38 (84.4)

4 (40)

Race
White
Black or African American

14 (82.4)

9 (90)

9 (81.8)

6 (85.7)

2 (11.8)

1 (10)

1 (9.1)

0 (0)

4 (8.9)

Other

1 (5.9)

0 (0)

0 (0)

1 (14.3)

2 (4.4)

Unknown or not reported

0 (0)

0 (0)

1 (9.1)

0 (0)

1 (2.2)

2 (11.8)

0 (0)

5 (45.5)

1 (14.3)

8 (17.8)

15 (88.2)

10 (100)

Ethnicity
Hispanic or Latino
Not Hispanic or Latino

6 (54.5)

5 (71.4)

36 (80)

0 (0)

0 (0)

0 (0)

1 (14.3)

1 (2.2)

Non-obese

0 (0)

7 (70)

8 (72.7)

1 (14.3)

16 (35.6)

Obese

0 (0)

3 (30)

2 (18.2)

6 (85.7)

11 (24.4)

17 (100)

0 (0)

1 (9.1)

0 (0)

18 (40)

Ethnicity unknown or not
reported
Obese statusf

Unavailable/not applicable

Gestational age was reported for all children <120 days postnatal age (PNA). For children ≥120 days PNA, gestational age was reported, if available.
Depicted values are representative of 7 subjects with postnatal ages of <2 years.
b
Postmenstrual age computed as the sum of gestational and postnatal age. A gestational age of 40 weeks was imputed for subjects in whom gestational
age was missing.
c
Body mass index was not reported for 2 subjects. Depicted values are representative of 16, 10, 10 and 7 subjects with PNA of <2 years, 2–<6 years, 6–
<12 years, and ≥12 years, respectively.
d
Albumin (serum) was not reported for 16 subjects. Depicted values are representative of 11, 7, 8 and 3 subjects with PNA of <2 years, 2–<6 years, 6–
<12 years, and ≥12 years, respectively.
e
Serum creatinine was not reported for 2 subjects. Depicted values are representative of 17, 10, 11 and 5 subjects with PNA of <2 years, 2–<6 years, 6–
<12 years, and ≥12 years, respectively.
f
Obesity defined as a body mass index ≥95th percentile for age and sex from Centers of Disease Control (CDC) growth charts.41
a
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TABLE 2

Summary of PK samples

Sample collection conditions

a slight trend towards higher clearance values among male participants
was observed (Figure 1B). No discernible patterns associated with

n

obesity status or race were denoted (Figures 1C, D). Following direct

Feeding status
Fasteda

32

Fed

51

Formulation

covariate testing (forward selection and backward elimination), only
PMA met the threshold for model inclusion (Supplementary Table S2).
This model, which included PMA (sigmoid Emax submodel) and WT
(fixed allometric exponent, 0.75), was subsequently denoted as the full

Suspensionb

14

model. As a final step, we compared the full model to an alternative

Tablet

31

model where the allometric exponent on WT was estimated rather

Crushed tablet

33

than fixed. The alternative model resulted in a decrease in the OFV by

5

2.7 compared to the full model and produced similar goodness-of-fit

Capsule

plots (Supplementary Figure S2). However, the estimated typical CL/F,

Route
Oral

50

which is representative of a 70 kg subject at full maturation, differed

Nasogastric/orogastric tube

14

between the two models: 21.6 vs. 16.8 L/h for the full and alternative

Transpyloric tube

10

models, respectively. A previously developed adolescent PopPK model

Gastrostomy tube

7

Gastrostomy-jejunostomy tube

2

Total

83

a

No food intake 2 hours prior to drug administration.
b
Extemporaneous preparation.

of distribution (V/F) and Ka were not estimated due to high shrinkage

for olanzapine reported typical CL/F estimates of 13.6 L/h (female
adolescents) and 17.5 L/h (male adolescents); values that are comparable to the alternative model.25 Therefore, considering its external
validity with respect to the published literature, the alternative model
was defined as the final irreducible model. Model equations for the
final model are described in Equations (3)–(5):


K a h − 1 = 0:758

ð3Þ

values.
Figure 1 displays random-effect terms for CL/F (ETACL/F) from the
base model against selected covariates. CL/F values among younger
participants were lower than typical model estimates (Figure 1A). Also,

F I G U R E 1 Base PopPK model
apparent clearance random-effect terms
(ETACL/F) vs. selected covariates:
(A) postmenstrual age; (B) sex;
(C) obesity status; and (D) race. Dashed
line represents a locally estimated
scatterplot smoothing (LOESS) line







WT i 0:486
PMAi 3:97
CL=Fi L  h − 1 = 16:8 
 3:97
 exp ηi,CL=F
3:97
70 kg
70
+ PMAi
ð4Þ
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V=Fi ðLÞ = 663 

WT i
70 kg

3.3

1
ð5Þ

|

Optimal paediatric dosing simulations

The derived optimized paediatric dosing regimen used weightnormalized doses for children ≤6 months (PNA) or <15 kg and fixed

where, ηi,CL/F is the random-effect term associated with CL/F, WTi is

doses for children ≥15 kg (Table 5). Since the PK of olanzapine was

body weight (kg) and PMAi is postmenstrual age in weeks for the ith

described using a linear PK model, the proposed dosing regimen and

subject. Estimated PopPK parameters and bootstrap approximations

simulation-based graphical plots for the 5 mg dose (Supplementary

for the final model are listed in Table 3. Model parameter estimates

Figure S3) represent a superposition of the 2.5 mg dose (Figure 4).

based on the entire dataset were within 7% and 12% of median boot-

Median AUC values across the different paediatric dosing groups fell

strap approximations for fixed- and random-effect parameters,

within 80–125% of the adult reference value (Figure 4A). A similar

respectively. The bootstrap 95% confidence interval for the effect of

finding was also observed when median exposures were summarized

WT on CL/F (θCL,WT) spanned from −0.541 to 0.796. Imprecision of

across the age range of 0.2–19 years (Figure 4B). Median reference

the bootstrap estimate was unsurprising considering the relatively

exposures in adolescents, derived based on Lobo et al.’s published

small sample size and the need for bootstrap samples to contain par-

PopPK model, were 24% higher compared to adult reference values.

ticipants with a diverse range of body sizes to provide an appropriate

This observation was consistent with Lobo et al.’s investigation, where

estimate of θCL,WT (i.e., its precision depends on a specific feature of

simulated olanzapine exposures were observed to be 27% higher in

the original sampling process).51 Comparatively, the estimate obtained

adolescents compared to adults.25

from the entire dataset (including all participants) was determined

Median exposures for the 966 virtual paediatric subjects from the

with adequate precision (RSE = 36%). Goodness-of-fit plots for the

≥50 kg dosing group, which comprised exclusively adolescent subjects

final PopPK model demonstrated an appropriate fit with observed

(i.e., ≥12 years), was comparable to reference adolescent values

data (Figure 2).

derived from Lobo et al.’s model.25 For example, after administration

When scaled to 70 kg, individualized apparent clearance esti-

of 2.5 mg, median plasma exposures were 153.6 and 170.1 ng*h/mL

mates (CL70kg/F) were statistically different between age groups

for the ≥50 kg dosing group and the adolescent reference group,

(Kruskal-Wallis test; P-value < .05; Table 4). Post-hoc statistical testing

respectively. This result demonstrates the external agreement

indicated CL70kg/F values were similar between younger age groups

between simulated exposures generated from our model and Lobo

(2 to <6 years PNA and 6 to <12 years PNA) and adolescents

et al.’s adolescent PopPK model.25 Dosages defined by the proposed

(≥12 years PNA) except for infants (<2 years PNA), where values were

dosing strategy (Table 5) were within a comparable range to standard

significantly lower compared to adolescents (Kruskal-Wallis test; P-

of care dosages administered to subjects within the observed study

value < .05, Bonferroni-corrected). A parabolic relationship between

cohort. For example, application of the proposed dosing strategy

olanzapine half-life and PNA was observed (Table 4 and Figure 3).

towards study participants would result in mean (range) olanzapine

Longer half-lives were observed in infants <5 months and children

dosages of 0.054 (0.02–0.08) and 0.11 (0.04–0.16) mg/kg for strate-

≥6 years. Comparatively, shorter half-lives were observed for partici-

gies that target similar exposures to 2.5 and 5 mg doses in adults,

pants aged 6 months to <6 years.

respectively. Of note, both dosing strategies (Table 5) recommend

TABLE 3

Final population PK model parameter estimates

Parameter

Estimate

RSEa (%)

2.5th percentile

Bootstrap median

97.5th percentile

8.7

16

26.5

Structural model
KA (1/h)

0.758

FIX

CL/F (L/h, 70 kg)

16.8

21

V/F (L, 70 kg)

663

13

523.3

677.3

914.1

TM50 (weeks)

70

16

52.5

69.8

317.3

HILL

3.97

23

2.08

4.15

7.08

θCL,WT

0.486

36

−0.541

0.455

0.796

ωCL/F2 (CV% b)

0.309 [60.2%]

38

0.035 [18.9%]

0.283 [57.2%]

0.688 [99.5%]

ε1 – proportional error

0.0772

39

0.019

0.069

0.177

ε22 – additive error

1.51

77

0.283

1.496

6.493

Random effects

2

CL/F, clearance; CV, coefficient of variation; RSE, relative standard error; V/F, apparent volume of distribution; TM50, maturation half-life; HILL, hill coefficient; θCL,WT, exponent modulating the influence of weight on apparent clearance.
a
Summary of 982 run of 1000 bootstrap runs that converged with ≥3 significant digits.
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b
CV% = 100  expðω2 Þ −1:
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F I G U R E 2 Goodness-of-fit plots for the final PopPK model: (A) observed vs. population predicted concentrations; (B) observed vs. individual
predicted concentrations; (C) conditional weighted residuals vs. population predicted concentrations; and (D) conditional weighted residuals vs.
time after last dose. In (A) and (B), the line of identity is depicted by the solid line. In all subplots, dotted lines depict locally estimated scatterplot
smoothing (LOESS) lines

TABLE 4

Individual empiric Bayesian post-hoc parameter estimates from the final population PK model

PNA (years)

n

CL/F (L/h/kg)a

<2 years

17

0.35 (0.14–1.41)

7.86 (2.32–31.39)

18.56 (4.65–46.65)

2–<6 years

10

0.50 (0.18–1.7)

15.16 (7.23–50.31)

13.36 (3.86–35.86)

6–<12 years

11

0.24 (0.15–0.78)

13.96 (6.34–44.71)

26.92 (8.42–42.72)

7

0.23 (0.12–0.47)

18.69 (8.74–34.01)

28.93 (14.11–56.44)

45

0.37 (0.12–1.7)

12.79 (2.32–50.31)

17.65 (3.86–56.44)

≥12 years
Overall

CL70kg/F (L/h)a

Half-life (h)a

a

Data are expressed as median (min-max).
PNA, postnatal age; CL/F, olanzapine apparent clearance; CL70kg/F, olanzapine apparent clearance scaled to 70 kg

lower olanzapine dosages for subjects ≤6 months postnatal age

4

|

DI SCU SSION

than were administered per standard of care (Supplementary
Figure S4). Correspondingly, model simulations depicted higher

Using opportunistically-collected PK samples, our investigation char-

AUC values for children ≤6 months receiving the median standard

acterized the PopPK of enterally-administered olanzapine in children

of care dosage from this study (0.1 mg/kg) compared to estimates

ranging from 2 months to 19 years (PNA). To our knowledge, this is

derived

the first report of the PK of olanzapine in children <10 years. Similar

from

Figure S5).

the

proposed

dosing

strategy

(Supplementary

to other published PopPK models for olanzapine in adolescents and
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F I G U R E 3 Individualized half-life estimates vs. postnatal age
based on the final PopPK model

T A B L E 5 Optimized paediatric dosing to achieve comparable
plasma exposures to adults
Group
2–6 months (postnatal age)
<15 kg

c

2.5 mga

5 mgb

0.0375 mg/kg

0.075 mg/kg

0.075 mg/kg

0.15 mg/kg

15–29 kgc

1.25 mg

2.5 mg

30–50 kgc

1.875 mg

3.75 mg

≥50 kgc

2.5 mg

5 mg

a

Paediatric dosages to target an area under the plasma concentration–time
curve comparable to healthy adult volunteers receiving a 2.5 mg oral dose.
b
Paediatric dosages to target an area under the plasma concentration–time
curve comparable to healthy adults volunteers receiving a 5 mg oral dose.
c
Dosing applicable to subjects ≥7 months, postnatal age.

adults, we found a one-compartment structural model was sufficient
to characterize the PK of olanzapine.25,29 Furthermore, the estimated
typical apparent clearance for a 70 kg adult derived from our model
(16.8 L/h) was comparable to previous PK analyses in adult nonsmoking healthy volunteers, Alzheimer's disease patients and schizo-

F I G U R E 4 Area under the plasma concentration–time curve
(AUC0-inf) simulations based on the proposed paediatric dosing
scheme (Table 5) that targets olanzapine exposures similar to adults
and adolescents receiving 2.5 mg (oral). Simulated AUC0-inf values
were computed for a virtual population consisting of 4000 virtual
subjects with ages and weights truncated towards the demographics
of the current study (i.e., 0.17–19 years postnatal age; 4–111 kg body
weight) using the developed paediatric PopPK model. In subplot A,
AUC0-inf values are summarized between different paediatric dosing
groups (no fill). Reference adolescent exposures simulated based on a
previously developed adolescent PopPK model (Lobo et al.25) were
computed using a virtual population of 1000 adolescent subjects and
an oral dose of 2.5 mg (grey fill). In subplot B, the running 50th
percentile (median) of simulated AUC0-inf values generated from the
developed paediatric PopPK model are displayed by age (4000 virtual
subjects; solid yellow line). The average AUC0-inf for non-smoking
adults (red solid line) along with 80% and 125% thresholds for this
value (red dashed lines) are display for reference [46–48]

phrenia patients that report mean clearance values between 16.1 and
20 L/h.29,46–48 In contrast, our model overpredicted apparent clearance values compared to a PK analysis by Grothe et al., who examined

debated topic in current literature.38,52,53 Despite the limited size of

olanzapine disposition in eight children aged 10–18 years with

our analysis dataset (45 participants; 83 samples) and the finding that

treatment-resistant schizophrenia.24 For these subjects, the median

both theoretical and estimated exponent models provided similar fits

(range) typical apparent clearance estimate from our model was 15.5

to the data (Supplementary Figure S2), we opted to use an estimated

(14.1–21.1) L/h; whereas, the study estimated value, determined by

exponent (i.e., 0.486) to describe the relationship between weight and

non-compartmental analysis, was 9.35 (5.8–14.3) L/h.24 The aetiology

olanzapine clearance for two reasons. First, use of an estimated expo-

for this discrepancy is not entirely clear as our study also included par-

nent provided a typical clearance estimate (scaled to a 70 kg subject)

ticipants of a similar age. Of note, however, typical apparent clearance

that was in better agreement with values from two published PopPK

estimates generated by a competing olanzapine PopPK model devel-

models for olanzapine in adults and adolescents that were developed

oped in adolescents also overpredicted clearance values compared to

using datasets comprising >100 subjects each.25,29 Second, our

25

Grothe et al.’s study.

For example, the median (range) typical appar-

dataset included participants with consistent representation along the

ent clearance estimate for the eight children based on Lobo et al.’s

developmental trajectory (from infants to adolescents) and a diverse

25

model was 15.3 (12–22.3) L/h.

The use of theoretical (i.e., fixed to 0.75) vs. estimated allometric
exponents for predicting drug clearance in children is a heavily

range of body sizes (from 4.2 to 111.7 kg) that permitted for estimation of the allometric exponent with a moderate degree of precision
(36% RSE).
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Individualized PK estimates (i.e., Bayesian post hoc) indicated the

both these covariates were tested in our analysis, neither met the

presence of a parabolic relationship between olanzapine half-life and

criteria for model inclusion. Similarly, the power of our analysis to

age (Figure 3). This pattern can be attributed to the ontogeny of phys-

detect influential covariates related to different administration routes

iological processes modulating olanzapine hepatic clearance, which

and formulations was limited. Second, our dosing simulations were

have yet to reach full maturation in younger children. A similar trend

based on a racially homogeneous population (i.e., White-American pop-

is observed for sufentanil, a hepatically metabolized synthetic opioid,

ulation), representative of the demographics of the majority (84.4%)

which exhibits a shorter terminal half-life among infants and children

of study participants. As our final model did not include race as an influ-

compared to neonates and adults.54,55

ential covariate towards olanzapine PK, the generated population only

For olanzapine, current FDA labelling only includes indications for

contributed information pertaining to subject weight and age. Since the

children ≥10 years, indicating that olanzapine is exclusively adminis-

proposed dosing strategy utilized weight-based classifications for the

A high prevalence of off-label

majority of subjects (i.e., ≥7 months postnatal age), the use of different

use was observed in the current study cohort with only one partici-

virtual populations was not anticipated to exert a substantial effect on

pant receiving olanzapine for a regulatory-approved indication, schizo-

the results of the analysis. However, as PopPK models are empiric in

phrenia. For 10 participants, the indication for olanzapine therapy was

nature, caution should be exercised if applying such models to simulate

denoted as anxiety, while for the remaining 34 participants, the indi-

populations outside their scope of development. Third, the dataset did

cation was denoted as “other”. Among these subjects, the reported

not contain information pertaining to potentially influential covariates

indication of olanzapine use was agitation, delirium, nausea, sedation

such as interacting medications and smoking status. For example, co-

or weening of sedative medications, and unclear/not recorded for

administration of fluvoxamine in adults has been shown to decrease

13, 10, 5, 3 and 3 participants, respectively. Considering that even

olanzapine apparent clearance by 42%.59 Additionally, in adult smokers,

when administered for labelled indications in adults, studies offer

olanzapine apparent clearance was observed to be 55% higher relative

inconsistent evidence to support a relationship between olanzapine

to non-smokers.29 For our analysis, exclusion of smoking status as a

PK (e.g., plasma concentrations) and efficacy, development of a paedi-

covariate was not inferred to be of substantial impact considering the

atric dosing scheme targeting specific PK thresholds associated with

age range of study participants (i.e., prevalence of smoking anticipated

efficacy was implausible.19–23 Consequently, we chose to identify

to be minor). Lastly, the dosing strategy developed from this work is

paediatric doses that would achieve comparable exposures (AUC) to

based on PK considerations only. Since paediatric use of olanzapine is

adults and adolescents receiving regulatory-labelled initial doses.

frequently for off-label indications, where relationships between

When taking into account the lack of paediatric safety and efficacy

dose/systemic concentrations and efficacy need to be substantiated,

studies for olanzapine, especially in children <10 years, using such a

prospective safety and efficacy studies for paediatric indications of

dosing scheme cannot be fully supported. Drug safety profiles

interest are needed to fully support using such a dosing strategy.

12

tered off-label to children <10 years.

established in adults cannot be universally extrapolated to children;
studies examining adverse drug events associated with olanzapine
have demonstrated divergent patterns between adults and chil-

5

|

CONC LU SION

dren.9,56 For example, incidences of weight gain and sedation were
>10% higher in children (>10 years of age) compared to adults (abso9

Using opportunistically-collected PK samples, we developed a PopPK

lute risk difference). Correspondingly, a rational use of the proposed

model for enterally-administered olanzapine in subjects ranging from

dosing scheme would be to inform the development of pivotal safety

2 months to 19 years. Our analysis identified PMA and body weight

and efficacy studies in children.

as influential covariates for describing developmental changes in

For children ≥7 months PNA and ≥15 kg, the proposed dosing

olanzapine apparent clearance. Simulations from the final model were

scheme recommends fixed doses based on either full tablets (2.5 or

used to develop an age- and weight-based dosing scheme for children

5 mg) or fractions of tablets (½ or 3/4). Nevertheless, to maintain expo-

that provided comparable exposures to adults and adolescents. This

sure targets in children ≤6 months (PNA) or <15 kg, weight-

dosing scheme can serve as a guide for the development of prospec-

normalized (mg/kg) dosing would be required. Accurate administration

tive safety and efficacy studies to promote the judicious use of

of such dosages requires a flexible formulation such as suspension or

olanzapine in children.

solution. Although such a formulation is unavailable commercially,
information on extemporaneous preparation of an olanzapine suspen-
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sion is available in the literature.57,58
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